A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration.

Area of Science:

• Hematology
• Stem Cell Transplantation
• Cellular Therapy

Background:

• Autologous peripheral blood stem cell collection is difficult for
• poor mobilizers
• using granulocyte-colony-stimulating factor.
• Plerixafor offers an alternative but is expensive, and optimal mobilization strategies are needed.

Purpose of the Study:

• To evaluate a protocol for peripheral blood CD34 cell measurement on Day 4 of mobilization to optimize stem cell collection.
• To assess the impact of this protocol on mobilization efficiency and product quality.

Main Methods:

• A protocol measuring peripheral blood CD34 on Day 4 of mobilization was developed.
• The study compared outcomes in 26 patients before and 24 patients after protocol implementation.

Main Results:

• The protocol group showed significantly fewer collection days (1.25 vs. 2.42), lower blood volume processed (25.9 L vs. 57.2 L), and reduced product volume (324 mL vs. 691 mL).
• Lower red blood cell (RBC) content and granulocyte percentage were observed in the protocol group.
• No significant differences were found in demographics, baseline platelet count, or total CD34 yield.

Conclusions:

• A Day 4 peripheral blood CD34 assessment protocol enables preemptive plerixafor use to enhance mobilization.
• This strategy reduces collection time and processed blood volume.
• The protocol leads to a cleaner stem cell product with less RBC and granulocyte contamination.